References
- XARELTO® (Rivaroxaban) Tablets [Package Insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc; 2017.
- Eliquis [Package Insert]. Princeton, NJ: Bristol-Myers Squibb; 12, 2012.
- CarliG, FarsiA, ChiariniF, LippolisD, CortelliniG. Hypersensitivity reactions to non-vitamin K oral anticoagulants - a review of literature and diagnostic work-up proposal. Eur Ann Allergy Clin Immunol. 2019;51(1):7–14. doi:10.23822/EurAnnACI.1764-1489.8030417637
- WangT, ZwickerJI, AyC, et al. The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: guidance from the SSC of the ISTH. J Thromb Haemost. 2019;17(10):1772–1778. doi:10.1111/jth.1456431353841
- KearonC, AklEA, OrnelasJ, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315–352. doi:10.1016/j.chest.2015.11.026.26867832
- OrtelTL, NeumannI, AgenoW, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020;4(19):4693–4738. doi:10.1182/bloodadvances.202000183033007077
- ElsebaieMAT, van EsN, LangstonA, BüllerHR, GaddhM. Direct oral anticoagulants in patients with venous thromboembolism and thrombophilia: a systematic review and meta-analysis. J Thromb Haemost. 2019;17:645–656. doi:10.1111/jth.1439830690830
- SerraoA, LucaniB, MansourD, et al. Direct oral anticoagulants in patients affected by major congenital thrombophilia. Mediterr J Hematol Infect Dis. 2019;11(1):e2019044. PMID: 31308920; PMCID: PMC6613626. doi:10.4084/MJHID.2019.044.31308920
- UndasA, GoralczykT. Non-vitamin K antagonist oral anticoagulants in patients with severe inherited thrombophilia: a series of 33 patients. Blood Coagul Fibrinolysis. 2017;28(6):438–442. PMID: 28079536. doi:10.1097/MBC.000000000000061328079536
- ValanejadSM, DavisKA. Direct oral anticoagulants in select patients with hypercoagulable disorders. Ann Pharmacother. 2021;55(7):891–901. PMID: 33100017. doi:10.1177/1060028020968551.33100017
- NaranjoCA, BustoU, SellersEM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–245. doi:10.1038/clpt.1981.1547249508
- JosylnJA, KhattakFH, GeraciSA. A case of a reversible neurologic adverse reaction to apixaban confirmed by re-challenge. J Clin Med Res. 2018;10(6):523–526. doi:10.14740/jocmr3394w29707095
- SassonE, JamesM, RussellM, TodorovD, CohenH. Probable rivaroxaban-induced full body rash: a case report. J Pharm Pract. 2018;31(5):503–506.28803520
- CortelliniG, RossiF, LippolisD, CortelliniF, GavioliB, BallardiniG. Delayed hypersensitivity to new oral anticoagulants. Demonstration of cross reactivity for the drug category and definition of non-irritant concentrations for patch tests. Eur Ann Allergy Clin Immunol. 2018. doi:10.23822/EurAnnACI.1764-1489.71